Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment?
Open Access
- 7 January 2005
- journal article
- editiorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (1), 1-5
- https://doi.org/10.1002/art.20717
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W MiceThe Journal of Experimental Medicine, 2004
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- Treatment of ANCA-Associated VasculitisNew England Journal of Medicine, 2003
- The Role of Long-Lived Plasma Cells in AutoimmunityImmunobiology, 2002
- Granuloma formation, implications for the pathogenesis of vasculitis.Cleveland Clinic Journal of Medicine, 2002
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- WEGENERʼS GRANULOMATOSIS: STUDIES IN EIGHTEEN PATIENTS AND A REVIEW OF THE LITERATUREMedicine, 1973
- Effects of Corticosteroids on Immunity in Man I. DECREASED SERUM IgG CONCENTRATION CAUSED BY 3 OR 5 DAYS OF HIGH DOSES OF METHYLPREDNISOLONEJCI Insight, 1973
- Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis)BMJ, 1958